Public Health England Officially Introduces MenB Vaccine for Infants

United Kingdom
22 June 2015

Following the recommendation made by the JCVI on March 2014 to offer the Bexsero MenB vaccine to children at 2, 4 and 12 months, Public Health England announces that immunisation against meningococcal B disease (MenB) will be added to the childhood immunisation programme as part of the routine schedule in England and Scotland from 1 September 2015. A one-off catch-up programme for infants born between 1 May 2015 and 30 June 2015 will also be offered. 

More information can be found on the documents to download.

A  leaflet has been produced for years 9 to 13 (students aged 12 to 18) explaining the menigococcal disease and why there is a need to get vaccinated. It can also be downloaded. 

Related News & Events

  • United Kingdom

    JCVI recommends to extend vaccination against HPV to boys


    The Joint Committee on Vaccination and Immunisations (JCVI) has recommended that the HPV immunisation programme should be extended to cover boys.

    Read more
  • United Kingdom

    JCVI says YES to LAIV for preventing flu in children


    In August 2016, JCVI was asked to review updated data from the 2015/16 season in the UK and other countries, in light of emerging evidence of low effectiveness of the nasal spray vaccine, lower than inactivated vaccine, reported in the United States (US). After reviewing evidence from across the UK, Finland, Canada and the United States following the 2015/16 influenza season, much of which demonstrates good overall effectiveness, JCVI continues to recommend using the live attenuated influenza vaccine (LAIV, the nasal spray vaccine) for preventing flu in children and strongly supports the continuation of the UK childhood influenza immunisation programme. 

    Read more
  • United Kingdom

    New Recommendation on adult pneumococcal vaccination in the UK


    During 2015 the Joint Committee on Vaccination and Immunisation (JCVI) and its pneumococcal sub-committee have reviewed the adult pneumococcal vaccination programme. This interim position statement outlines JCVI’s considerations. The committee will consult stakeholders before producing a final statement.

    Read more